ResearcherChina Medical UniversityNo recent work listed

Shih‐Chang Tsai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9018-607X; OpenAlex author ID A5007405801. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2023: 1 paper

Papers 1

Efficacy of HMJ-38, a new quinazolinone analogue, against the gemcitabine-resistant MIA-PaCa-2 pancreatic cancer cells. Last author DOI 10.37796/2211-8039.1423 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

I‐Lu Lai · 1 shared paper, 2023 · strength 0.18
- Paper Efficacy of HMJ-38, a new quinazolinone analogue, against the gemcitabine-resistant MIA-PaCa-2 pancreatic cancer cells. DOI 10.37796/2211-8039.1423 ↗
Mann‐Jen Hour · 1 shared paper, 2023 · strength 0.18
- Paper Efficacy of HMJ-38, a new quinazolinone analogue, against the gemcitabine-resistant MIA-PaCa-2 pancreatic cancer cells. DOI 10.37796/2211-8039.1423 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.